Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Raquel Celis, Bernard Lauwerys et al.|The Lancet|2021Cited by 315
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19Thomas Bieber, Peter C. Taylor|Advances in Therapy|2022Cited by 58
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic IndicationsPeter C. Taylor, Andreas Wollenberg|Advances in Therapy|2023Cited by 38
The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cellsSam Weston, Peter C. Taylor|Clinical and Experimental Rheumatology|2020Cited by 16
Inflammatory disease microbiomes share a functional pathogenicity predicted by C-reactive proteinGraham J. Britton, Jeremiah J. Faith, Ilaria Mogno et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0